Heart failure & cardiomyopathies
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
Authors' conclusion
In the DELIVER trial, dapagliflozin safely reduced worsening HF or cardiovascular death across a broad range of baseline medication use, including among individuals with polypharmacy
Study context
- Population
- Symptomatic heart failure (HF) with LVEF >40%, by baseline medication use (nonpolypharmacy <5, polypharmacy 5 to 9, hyperpolypharmacy ≥10 medications)
- Participants
- 6,263 participants
- Comparison
- Dapagliflozin vs placebo, by number of concomitant medications
- Primary endpoint
- Worsening HF or CV death
Methodological detailspost hoc analysis, subgroup analysis by polypharmacy status
- Post hoc analysis
- Subgroup analysis by polypharmacy status
Primary result
As reported in the abstract
Worsening HF or CV death, by polypharmacy status
Dapagliflozin vs PlaceboHazard ratio (95% CI)
Nonpolypharmacy
0.88(0.58–1.34)
Polypharmacy
0.88(0.75–1.03)
Hyperpolypharmacy
0.73(0.60–0.88)
- Benefits consistent across the spectrum of total medication use
- P for interaction = 0.06
Further findings
Polypharmacy prevalence
- Polypharmacy
- 3,795 (60.6%)
- Hyperpolypharmacy
- 1,886 (30.1%)
- More medications associated with higher comorbidity burden and higher rates of primary outcome
Safety
Adverse events
- AEs increased with more medications but were not more frequent with dapagliflozin, regardless of polypharmacy status
Original publication
Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status. JACC Heart Fail. Published 21 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →